At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
|Slideshows|August 8, 2014
Advice to Young Oncologists
Author(s)ONCOLOGY's Editorial Board
In this slide show we present sage words for the young oncologist starting today from colleagues who are well-established in their fields. What advice would you give?
Advertisement
Advertisement
Related to this article
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
2
Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery
3
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
4
FDA OKs Pirtobrutinib in Frontline CLL/SLL
5